Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Completed · Phase 1

Conditions studied: Carcinoma, Renal Cell

In brief

This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.

Key facts

Study ID

NCT00372853

Run by

AstraZeneca

People needed

28

Starts

2006-11-01

Expected to finish

2010-05-01

Last updated by the study team

2012-06-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven renal cell carcinoma with metastases
• Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1

You may not qualify if…

• Prior treatment with more than one systemic therapy for metastatic renal cell carcinoma
• History of or known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening Computed Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) scan

Where it is running

• Research Site — Scottsdale, Arizona, United States
• Research Site — New Brunswick, New Jersey, United States
• Research Site — Cleveland, Ohio, United States
• Research Site — Greenville, South Carolina, United States
• Research Site — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.